Consensus Ionis Pharmaceuticals, Inc.

Stocks

IONS

US4622221004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:16:28 2026-09-14 EDT			5-day change	1st Jan Change
51.68 ^USD	-4.66%		-8.68%	-34.53%

09-10	Ionis Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-10-2026 08:45 AM
09-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $91 From $93	MT

Evolution of the Average Target: Ionis Pharmaceuticals, Inc.

Evolution of the Target Price: Ionis Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Ionis Pharmaceuticals, Inc.

7a8573915c592d.DeB8hMBRwvo1SYRFTSy2n95fLwDZVCjSRGGl5xSF4ho.WYwE9vEwqYhmHuwJJ3bcrrseF3TsDGOKdBGVqV3Q0Vw5sSTW8SSIgHIO8w~0988e102bcbe926ce29c5d98f1c62359

Analysts' recommendations: Ionis Pharmaceuticals, Inc.

09-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $91 From $93	MT
09-03	Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial	RE
07-13	RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	Analyst recommendations: Cubesmart, Fox Corporation, AMD, Crowdstrike, Micron…
07-09	Needham Adjusts Ionis Pharmaceuticals Price Target to $86 From $105, Maintains Buy Rating	MT
07-09	TD Cowen Adjusts Ionis Pharmaceuticals Price Target to $94 From $108, Maintains Buy Rating	MT
07-09	WINNERS & LOSERS: Astra down on failed test; Computacenter ups outlook	AN
04-30	Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating	MT
04-30	RBC Lifts Price Target on Ionis Pharmaceuticals to $100 From $95, Keeps Outperform Rating	MT
04-21	Canaccord Genuity Initiates Coverage on Ionis Pharmaceuticals With Buy Rating, $110 Price Target	MT
04-21	Analyst recommendations: Colgate-Palmolive, Intel, Netflix, Spotify, Dell…
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $111 From $100, Maintains Buy Rating	MT
12-17	RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
25-10-30	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
25-10-28	Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says	MT
25-10-16	Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating	MT
25-10-09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
25-10-08	Ionis Pharmaceuticals Shares Rise After JPMorgan Upgrade	MT
25-10-08	JPMorgan Upgrades Ionis Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $80 From $49	MT
25-10-08	Analyst recommendations: AMD, Freeport-Mcmoran, Intel, Otis, Elf Beauty…
25-09-26	Ionis Pharmaceuticals Shares Rise After Goldman Sachs Upgrade	MT
25-09-26	Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IONIS PHARMACEUTICALS, INC.					+55.37%
	LONZA GROUP AG					+29.55%
	REVOLUTION MEDICINES, INC.					+23.28%
	IQVIA HOLDINGS INC.					+5.54%
	BEONE MEDICINES AG					+24.9%
	CELLTRION, INC.					+50.52%
	ASCENDIS PHARMA A/S					+19.38%
	MEDPACE HOLDINGS, INC.					-0.97%
	EUROFINS SCIENTIFIC SE					+2.18%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+1.5%
	Average					+21.13%
	Weighted average by Cap.					+22.14%